You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema

Article Text

Article menu

Download PDFPDF

XML
Original article
Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema
  1. Sidney A Schechet1,
  2. Olufemi E Adams1,
  3. David A Eichenbaum2,3,
  4. Seenu M Hariprasad1
  1. 1Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois, USA
  2. 2Partner, Retina Vitreous Associates of Florida, St Petersburg, Florida, USA
  3. 3Ophthalmology, USF Health Morsani College of Medicine, Tampa, Florida, USA
  1. Correspondence to Dr Seenu M Hariprasad; Retina{at}uchicago.edu

Abstract

Objective To investigate if the mean central retinal thickness (CRT) amplitude, measured between visits, is consistently decreased when switching from discontinuous to continuous therapy for diabetic macular oedema (DME) following fluocinolone acetonide (FAc) administration.

Methods and analysis In this retrospective cohort study, all patients with DME treated with FAc at a single centre were included. The primary outcome was CRT amplitude changes measured at each visit prior to and after FAc administration. Secondary outcomes included average number of DME treatments before and after FAc injection, visual acuity and intraocular pressure changes.

Results Nineteen eyes were included. The mean (SD) follow-up after FAc was 399 (222) days. The mean (SD) CRT amplitude before FAc was 194.6 (114.90) µm, and following FAc administration, the amplitude decreased to 70.8 (94.23) µm (95% CI −189.5 to −58.1; p≤0.001). After FAc, the number of treatments required per month significantly decreased from an average of 1 treatment every 2.7 months to every 6 months (p=0.009).

Conclusion In patients with DME, the CRT amplitude values and number of treatments significantly decrease following FAc administration while maintaining vision. Further studies are needed to evaluate the significance of these interesting findings.

  • treatment medical
  • retina
  • pharmacology
  • macula
  • drugs

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/bmjophth-2019-000271

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors Substantial intellectual contributions to the content of this manuscript were made by the authors in the following areas. Planning the research question: SAS, OEA, SMH. Conducting the protocols described: SAS, OEA. Drafting, critical revision and final approval: SAS, OEA, DAE, SMH. Corresponding author and overall content guarantor: SMH.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests SAS and OEA report no financial disclosures. DAE is a consultant, investigator or on the speaker’s bureau for Genentech, Regeneron, Allergan, Clearside, Novartis, Alimera, Ophthotech, Notal Vision, Allegro, Eyepoint, Mylan, Chengdu, Orbit Biomedical and Adverum. DAE is also an equity/stockholder in Clearside, US Retina, Hemera Biopharmaceuticals and Boston Image Reading Center. SMH is a consultant or on the speaker’s bureau for Alcon, Allergan, Novartis, OD-OS, Clearside Biomedical, EyePoint Pharmaceuticals, Alimera Sciences, Spark and Regeneron.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.